Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT), an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines.
奥本海默开始报道Vaxart Inc.（纳斯达克股票代码：VXRT），这是一家专注于口服重组疫苗发现、开发和商业化的美国生物技术公司。
The analyst's bullish view is centered around optimism associated with attractive opportunities for Vaxart's 'differentiated' oral vaccine platform and key programs, such as the norovirus vaccine and COVID-19 vaccine.
分析师的看涨观点集中在乐观情绪上，乐观情绪与Vaxart的 “差异化” 口服疫苗平台和关键计划（例如诺如病毒疫苗和 COVID-19 疫苗）的诱人机会有关。
Oppenheimer initiated with an Outperform rating and a price target of $4, representing significant potential upside.
奥本海默最初的评级为跑赢大盘，目标股价为4美元，这意味着巨大的潜在上涨空间。
"VXRT is uniquely positioned as a leading company developing oral vaccines against COVID-19, supported by one of the largest BARDA-funded Project NextGen Awards," the analyst writes.
这位分析师写道：“作为一家开发针对 COVID-19 的口服疫苗的领先公司，VxRT 具有独特的地位，得到了巴尔达资助的最大的 NextGen 项目奖项之一。”
"We think oral vaccines hold unique properties that may complement intramuscular vaccines to fulfill global healthcare promise," the analyst adds.
该分析师补充说：“我们认为口服疫苗具有独特的特性，可以补充肌肉注射疫苗，兑现全球医疗保健承诺。”
Also Read: Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering.
另请阅读：Vaxart收购了价值4.53亿美元的Barda资助的项目，旨在通过股票发行筹集4000万美元。
Although norovirus poses significant global health and economic challenges, there is currently no approved vaccine.
尽管诺如病毒构成了重大的全球健康和经济挑战，但目前尚无获批准的疫苗。
With an estimated market potential of $5 billion-10 billion due to the unmet need, a norovirus vaccine could follow a path similar to RSV vaccines that have gained ACIP recommendations.
由于需求未得到满足，估计市场潜力为50亿至100亿美元，因此诺如病毒疫苗可能会走类似于获得ACIP推荐的呼吸道合胞病毒疫苗的道路。
Vaxart is developing a VP-1-based bivalent oral vaccine for norovirus. Oppenheimer sees strong potential in this area, citing the lack of approved vaccines despite the virus's significant health and economic impact.
Vaxart正在开发一种基于VP-1的诺如病毒双价口服疫苗。奥本海默认为该领域的潜力巨大，理由是尽管该病毒对健康和经济产生了重大影响，但仍缺乏批准的疫苗。
The analyst suggests that Vaxart's oral tablet could offer better immunity than traditional intramuscular vaccines, which have faced challenges. They also view Vaxart as a leader in norovirus vaccine development, positioning it for potential commercial success.
分析师认为，与面临挑战的传统肌肉注射疫苗相比，Vaxart的口服片剂可以提供更好的免疫力。他们还将Vaxart视为诺如病毒疫苗开发的领导者，为其潜在的商业成功做好了准备。
Price Action: VXRT stock is up 21% at $0.715 at the last check on Thursday.
价格走势：在周四的最后一次支票中，vxRT股价上涨21％，至0.715美元。
- Meta Shuts Down Tracking Tool CrowdTangle, Faces Bipartisan Criticism.
- Meta 关闭了追踪工具 CrowdTangle，面临两党的批评。
Don't miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you're a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
千万不要错过10月9日至10日在芝加哥市中心壮丽大道万豪酒店举行的Benzinga SmallCap会议上在动荡的市场中占据主导地位的机会。独家访问首席执行官演讲、与投资者的 1:1 会面以及顶级金融专家的宝贵见解。无论您是交易者、企业家还是投资者，该活动都提供了无与伦比的机会来扩大您的投资组合并与行业领导者建立联系。确保您的位置并立即获得门票！